Mark Masin

966 total citations
9 papers, 789 citations indexed

About

Mark Masin is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Mark Masin has authored 9 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Hematology. Recurrent topics in Mark Masin's work include Multiple Myeloma Research and Treatments (3 papers), Protein Degradation and Inhibitors (3 papers) and RNA modifications and cancer (2 papers). Mark Masin is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Protein Degradation and Inhibitors (3 papers) and RNA modifications and cancer (2 papers). Mark Masin collaborates with scholars based in Switzerland, United States and Germany. Mark Masin's co-authors include Olaf Groß, Jürg Tschopp, Amir S. Yazdi, Stefan K. Drexler, Manfredo Quadroni, Christina J. Thomas, Greta Guarda, Leonhard X. Heinz, Stefan Kunz and Jillian M. Rojek and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Immunity.

In The Last Decade

Mark Masin

9 papers receiving 782 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Masin Switzerland 7 500 306 115 106 95 9 789
Damian B. D’Silva Australia 8 568 1.1× 563 1.8× 58 0.5× 141 1.3× 72 0.8× 12 863
Lotte Spel Netherlands 14 300 0.6× 270 0.9× 72 0.6× 89 0.8× 236 2.5× 18 681
Konstantin Bogdanov Russia 9 671 1.3× 434 1.4× 106 0.9× 62 0.6× 75 0.8× 33 896
Konstantin Neumann Germany 13 300 0.6× 488 1.6× 54 0.5× 131 1.2× 63 0.7× 21 824
Sarang Tartey Japan 12 517 1.0× 422 1.4× 179 1.6× 52 0.5× 112 1.2× 15 882
Sonal Khare United States 12 711 1.4× 432 1.4× 51 0.4× 29 0.3× 108 1.1× 18 930
Francesco Staehli Switzerland 5 621 1.2× 755 2.5× 34 0.3× 105 1.0× 123 1.3× 5 1.1k
Jiing-Kuan Yee United States 8 862 1.7× 175 0.6× 102 0.9× 85 0.8× 80 0.8× 8 1.1k
Tewfik Miloud Germany 10 323 0.6× 203 0.7× 29 0.3× 78 0.7× 83 0.9× 13 751

Countries citing papers authored by Mark Masin

Since Specialization
Citations

This map shows the geographic impact of Mark Masin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Masin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Masin more than expected).

Fields of papers citing papers by Mark Masin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Masin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Masin. The network helps show where Mark Masin may publish in the future.

Co-authorship network of co-authors of Mark Masin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Masin. A scholar is included among the top collaborators of Mark Masin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Masin. Mark Masin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Gay, Francesca, Meletios Α. Dimopoulos, Xiao‐Jun Huang, et al.. (2023). P-137 A phase 3, two-stage, randomized study of iberdomide maintenance versus lenalidomide maintenance post autologous stem cell transplantation in newly diagnosed multiple myeloma: EXCALIBER-maintenance. Clinical Lymphoma Myeloma & Leukemia. 23. S111–S111. 2 indexed citations
2.
Cheng, Yiming, Yongjun Xue, Lu Chen, et al.. (2022). Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma. British Journal of Clinical Pharmacology. 89(1). 316–329. 6 indexed citations
4.
Masin, Mark, Jessica Vázquez, Simona Rossi, et al.. (2014). GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. DSpace@MIT (Massachusetts Institute of Technology). 1 indexed citations
5.
Masin, Mark, Jessica Vázquez, Simona Rossi, et al.. (2014). GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Cancer & Metabolism. 2(1). 11–11. 124 indexed citations
6.
Groß, Olaf, Amir S. Yazdi, Christina J. Thomas, et al.. (2012). Inflammasome Activators Induce Interleukin-1α Secretion via Distinct Pathways with Differential Requirement for the Protease Function of Caspase-1. Immunity. 36(3). 388–400. 378 indexed citations
7.
Drexler, Stefan K., Mark Masin, Aubry Tardivel, et al.. (2012). Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proceedings of the National Academy of Sciences. 109(45). 18384–18389. 119 indexed citations
8.
Pasqual, Giulia, Jillian M. Rojek, Mark Masin, Jean‐Yves Chatton, & Stefan Kunz. (2011). Old World Arenaviruses Enter the Host Cell via the Multivesicular Body and Depend on the Endosomal Sorting Complex Required for Transport. PLoS Pathogens. 7(9). e1002232–e1002232. 126 indexed citations
9.
Pasqual, Giulia, Jillian M. Rojek, Mark Masin, Jean‐Yves Chatton, & Stefan Kunz. (2011). Correction: Old World Arenaviruses Enter the Host Cell via the Multivesicular Body and Depend on the Endosomal Sorting Complex Required for Transport. PLoS Pathogens. 7(9). 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026